NovaBay Pharmaceuticals to Hold Third Quarter 2018 Conference Call on November 14, 2018

Date : 11/07/2018 @ 11:50AM
Source : Business Wire
Stock : NovaBay Pharmaceuticals Inc New (NBY)
Quote : 0.6252  0.0004 (0.06%) @ 4:07PM

NovaBay Pharmaceuticals to Hold Third Quarter 2018 Conference Call on November 14, 2018

NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart

1 Year : From Oct 2018 to Oct 2019

Click Here for more NovaBay Pharmaceuticals Charts.

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces that it will report third quarter 2018 financial results after market close on Wednesday, November 14. Management will hold an investment community conference call that day to discuss financial results and provide a Company update.

  DATE:       Wednesday, November 14 TIME: 4:30 p.m. ET / 1:30 p.m. PT DIAL IN: 800-608-8202 from within the U.S. 702-495-1913 from outside the U.S. Enter conference identification number 5709629  

The live call also will be available at http://novabay.com/investors/events. A replay of the call will be available beginning two hours after its completion through 11:59 p.m. Eastern time November 20, 2018, by dialing 855-859-2056 from within the U.S. or 404-537-3406 from outside the U.S. and entering the conference identification number 5709620. The call will also be archived at http://novabay.com/investors/events.

About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focused on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX® family of products and the AGANOCIDE® compounds. The Neutrox family of products includes AVENOVA® for the eye care market, NEUTROPHASE® for the wound care market and CELLERX® for the aesthetic dermatology market. The Aganocide compounds, still under development, have target applications in dermatology and urology.

Socialize and Stay informed on NovaBay’s progress:Like us on FacebookFollow us on TwitterConnect with NovaBay on LinkedInJoin us on Google+Visit NovaBay’s Website

NovaBay ContactsFor NovaBay Avenova purchasing information:Please Call us toll free: 1-800-890-0329 or email sales@avenova.com.www.Avenova.com

NovaBay Pharmaceuticals, Inc.Jack McGovern, 510-899-8800Chief Executive Officer andChief Financial Officerjmcgovern@novabay.comorInvestor ContactLHA Investor RelationsJody Cain, 310-691-7100jcain@lhai.com

Latest NBY Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.